• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

LipoSeuticals closes Series A for novel drug delivery tech

June 29, 2017 By Sarah Faulkner

Prescription drugsLipoSeuticals said today that it closed a financing round for an undisclosed amount led by Hong Kong-based life sciences fund, Delos Capital.

The company has developed a sugar-lipid polymer-based formulation, Sulocence, which boosts drug stability and solubility. LipoSeuticals said it is applying the drug delivery technology to the reformulation of an array of marketed specialty drugs.

In connection with the round, Lan Bo Chen of Delos Capital plans to join the company’s board.

“This exciting opportunity enables the LSI management team and Delos to embark on our stated mission of building a premier specialty pharmaceutical company that will develop, manufacture and market proprietary branded formulations of select known drug products,” Chen said in prepared remarks. “We intend to leverage our deep and strong relationships in the pharmaceutical arena and invest wisely in manufacturing facilities, R&D laboratories and the robust drug pipeline under development at LipoSeuticals in order to build and grow a world-class pharmaceutical organization.”

“I am extremely proud of the company that we have built over the course of the past 5 years with the help of the entire LSI team of scientists and staff,” founder & CEO Nian Wu added. “We are delighted that we now have the expertise and financial resources to build on LSI’s solid foundation. Our Sulocence technology has tremendous potential for improving many drug products that currently suffer from poor solubility, stability, and side effects. We are confident that with the help of Delos’ financial resources, experience and strong relationships within the Life Science Industry, we will achieve sustainable success.”

Filed Under: Featured, Funding Roundup, Pharmaceuticals Tagged With: liposeuticals

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS